Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 4,326 Shares of Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 4,326 shares of the company’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $4.41, for a total transaction of $19,077.66. Following the transaction, the chief executive officer now owns 220,119 shares in the company, valued at approximately $970,724.79. This trade represents a 1.93 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Richard Nolan Townsend also recently made the following trade(s):

• On Tuesday, December 10th, Richard Nolan Townsend sold 2,500 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $8.20, for a total transaction of $20,500.00.

Lexeo Therapeutics Stock Performance

Shares of LXEO stock opened at $3.89 on Friday. The stock’s fifty day moving average is $5.76 and its two-hundred day moving average is $8.12. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. Lexeo Therapeutics, Inc. has a fifty-two week low of $3.84 and a fifty-two week high of $19.50.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on LXEO. Royal Bank of Canada restated an “outperform” rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, January 21st. Leerink Partners cut their price target on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Wednesday, November 13th. Chardan Capital increased their price target on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, HC Wainwright increased their price target on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $23.80.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LXEO. Janus Henderson Group PLC increased its stake in shares of Lexeo Therapeutics by 15.3% in the 4th quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company’s stock worth $28,508,000 after acquiring an additional 576,059 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in shares of Lexeo Therapeutics in the 3rd quarter worth $11,307,000. Vestal Point Capital LP increased its stake in shares of Lexeo Therapeutics by 41.2% in the 4th quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company’s stock worth $7,896,000 after acquiring an additional 350,000 shares during the last quarter. Woodline Partners LP increased its stake in shares of Lexeo Therapeutics by 0.8% in the 4th quarter. Woodline Partners LP now owns 858,691 shares of the company’s stock worth $5,650,000 after acquiring an additional 6,730 shares during the last quarter. Finally, Verition Fund Management LLC increased its stake in shares of Lexeo Therapeutics by 84.5% in the 3rd quarter. Verition Fund Management LLC now owns 777,320 shares of the company’s stock worth $7,027,000 after acquiring an additional 355,928 shares during the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.